An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Transitioning to Lemborexant in Japanese Subjects With Insomnia
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Lemborexant (Primary) ; GABA A receptor agonists; Hypnosedatives; Ramelteon; Suvorexant
- Indications Insomnia
- Focus Therapeutic Use
- 18 Apr 2024 Results assessing the success rate of direct transitioning from Z-drugs to a competitive dual orexin receptor antagonist, lemborexant (LEM), in subjects with insomnia presented at the 76th Annual Meeting of the American Academy of Neurology 2024
- 13 Mar 2023 Status changed from recruiting to completed.
- 02 Oct 2021 Status changed from not yet recruiting to recruiting.